Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CNI-Free GVHD Prevention in Haploidentical HCT
NCT03018223Phase 1Completed
- Sponsor
- Moffitt Cancer Center
- Start
- Jan 2017
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of cyclophosphamide, sirolimus and mycophenolate mofetil in graft-versus-host disease (GVHD), sponsored by Moffitt Cancer Center. Started Jan 2017; status: completed.
02
Drugs
cyclophosphamidesirolimusmycophenolate mofetil
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT03018223.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03018223.